This piece argues that President Trump’s move to expand Medicaid and Medicare coverage for prescription weight loss drugs is a big win, but it also warns about dangerous knockoffs sold as compounded medications and urges swift enforcement to protect patients from unsafe, untested products.
Millions of Americans are battling their weight with varying success, and easy solutions are tempting. We’ve both lived lives where discipline kept us fit, but most people do not have that luxury and deserve safe medical help when they need it.
Recent prescription drugs have delivered real results for many patients, and the White House action to expand coverage is a win for public health and common sense. Making effective treatments like Zepbound and Wegovy available through Medicaid and Medicare removes a major access barrier for lower-income Americans.
That victory is worth celebrating, but there’s an ugly side to the market that needs a hard look: compounded knockoffs being sold online and through sketchy pharmacies. These products are not the brand-name medications and they have not gone through the rigorous testing that earns FDA approval, which leaves patients exposed to unknown risks.
The FDA itself warns plainly: “Compounded drugs are not FDA approved, which means the agency does not verify their safety, effectiveness or quality…” This is not a fine print problem; it’s a fundamental public safety gap that requires decisive action from regulators and lawmakers.
During the shortages between 2022 and 2024, the agency allowed compounding to fill gaps, which was a reasonable short-term measure at the time. Once supply stabilized, compounders were told to stop. Instead of complying, many found a workaround under the label of “personalized medicine” and kept selling formulas that pair weight-loss agents with other drugs.
Those scrambled cocktails have never been tested in clinical trials and their safety profiles are unknown, so patients are effectively guinea pigs when they buy them. The risk is magnified when production and distribution chains originate overseas, with numerous reports pointing to foreign manufacturing in places like China for some of these suspect compounds.
From a Republican standpoint, this is where conservative principles of personal responsibility meet the role of a functional government: protect citizens from fraud and unsafe products while preserving access to proven therapies. President Trump and HHS Secretary Robert Kennedy should use their authority to shut down pharmacies and suppliers that peddle these unapproved mixtures and to tighten enforcement around compounding operations.
Practical steps include stepped-up inspections, coordinated border controls to stop illegal imports, clear enforcement actions against bad actors, and guidance that closes the “personalized medicine” loophole being exploited for profit. The goal is simple: keep legitimate access to effective weight loss meds while removing dangerous, unregulated substitutes from the market.
Patients who need help losing weight should be able to trust their prescriptions and the professionals who fill them, not be tempted by cheap online ads promising miracles at a discount. It’s time for leadership to pair expanded access with relentless enforcement so Americans get safe, proven care, not unverified compounds that put health at risk.
